uniQure (NASDAQ:QURE) Insider Sells $13,891.50 in Stock

uniQure (NASDAQ:QURE) insider Walid Abi-Saab sold 1,350 shares of the company’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $13,891.50. Following the completion of the sale, the insider now directly owns 151,903 shares of the company’s stock, valued at $1,563,081.87. This trade represents a 0.88 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

uniQure Stock Up 6.7 %

NASDAQ QURE traded up $0.76 during trading hours on Wednesday, reaching $12.09. 1,028,349 shares of the company’s stock traded hands, compared to its average volume of 1,042,863. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The firm has a 50-day simple moving average of $14.80 and a 200 day simple moving average of $9.89. The firm has a market cap of $589.30 million, a PE ratio of -2.44 and a beta of 0.38.

Wall Street Analyst Weigh In

QURE has been the topic of a number of recent research reports. Wells Fargo & Company reduced their price objective on uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Friday, February 28th. The Goldman Sachs Group boosted their price objective on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 12th. Leerink Partners increased their target price on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. Cantor Fitzgerald upped their target price on uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, December 10th. Finally, StockNews.com raised shares of uniQure to a “sell” rating in a research report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $38.89.

Hedge Funds Weigh In On uniQure

Several large investors have recently made changes to their positions in QURE. China Universal Asset Management Co. Ltd. raised its holdings in uniQure by 9.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after buying an additional 969 shares during the last quarter. Tudor Investment Corp ET AL raised its holdings in uniQure by 5.9% in the 4th quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company’s stock worth $438,000 after acquiring an additional 1,371 shares during the last quarter. Wells Fargo & Company MN lifted its position in uniQure by 13.9% in the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock valued at $217,000 after acquiring an additional 1,503 shares in the last quarter. Northern Trust Corp lifted its position in uniQure by 2.1% in the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock valued at $1,688,000 after acquiring an additional 1,923 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in uniQure by 6.0% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company’s stock valued at $1,253,000 after purchasing an additional 3,996 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.